Molecular-targeted therapy in malignant melanoma

References

• Jemal A, Thun MJ, Ries LA et al. Annual report to the nation on the status of cancer, 1975–2005, featuring trends in lung cancer, tobacco use, and tobacco control. J. Natl Cancer Inst.100(23), 1672–1694 (2008).
   PubMed Web of Science ®Google Scholar
• Atkins MB, Lotze MT, Dutcher JP et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol.17(7), 2105–2116 (1999).
   PubMed Web of Science ®Google Scholar
• Atkins MB, Hsu J, Lee S et al. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon α-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J. Clin. Oncol.26(35), 5748–5754 (2008).
   PubMed Web of Science ®Google Scholar
• Camacho LH, Antonia S, Sosman J et al. Phase I/II trial of tremelimumab in patients with metastatic melanoma. J. Clin. Oncol.27(7), 1075–1081 (2009).
   PubMed Web of Science ®Google Scholar
• Hodi FS, Mihm MC, Soiffer RJ et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc. Natl Acad. Sci. USA100(8), 4712–4717 (2003).
   PubMed Web of Science ®Google Scholar
• Ribas A, Camacho LH, Lopez-Berestein G et al. Antitumor activity in melanoma and anti-self responses in a Phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J. Clin. Oncol.23(35), 8968–8977 (2005).
   PubMed Web of Science ®Google Scholar
• Serrone L, Zeuli M, Sega FM, Cognetti F. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. J. Exp. Clin. Cancer Res.19(1), 21–34 (2000).
   PubMed Web of Science ®Google Scholar
• Chapman PB, Einhorn LH, Meyers ML et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J. Clin. Oncol.17(9), 2745–2751 (1999).
   PubMed Web of Science ®Google Scholar
• Chiarion Sileni V, Nortilli R, Aversa SM et al. Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients. Melanoma Res.11(2), 189–196 (2001).
   PubMed Web of Science ®Google Scholar
• Creagan ET, Suman VJ, Dalton RJ et al. Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma. J. Clin. Oncol.17(6), 1884–1890 (1999).
   PubMed Web of Science ®Google Scholar
• Falkson CI, Ibrahim J, Kirkwood JM et al. Phase III trial of dacarbazine versus dacarbazine with interferon α-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon α-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. J. Clin. Oncol.16(5), 1743–1751 (1998).
   PubMed Web of Science ®Google Scholar
• McDermott DF, Sosman JA, Gonzalez R et al. Double-blind randomized Phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J. Clin. Oncol.26(13), 2178–2185 (2008).
   PubMed Web of Science ®Google Scholar
• Middleton MR, Lorigan P, Owen J et al. A randomized Phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma. Br. J. Cancer82(6), 1158–1162 (2000).
   PubMed Web of Science ®Google Scholar
• Middleton MR, Grob JJ, Aaronson N et al. Randomized Phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J. Clin. Oncol.18(1), 158–166 (2000).
   PubMed Web of Science ®Google Scholar
• Zimpfer-Rechner C, Hofmann U, Figl R et al. Randomized Phase II study of weekly paclitaxel versus paclitaxel and carboplatin as second-line therapy in disseminated melanoma: a multicentre trial of the Dermatologic Co-operative Oncology Group (DeCOG). Melanoma Res.13(5), 531–536 (2003).
   PubMed Web of Science ®Google Scholar
• Walker L, Schalch H, King DM et al. Phase II trial of weekly paclitaxel in patients with advanced melanoma. Melanoma Res.15(5), 453–459 (2005).
   PubMed Web of Science ®Google Scholar
• Retsas S, Newton KA, Westbury G. Vindesine as a single agent in the treatment of advanced malignant melanoma. Cancer. Chemother. Pharmacol.2(4), 257–260 (1979).
   PubMed Web of Science ®Google Scholar
• Whitehead RP, Moon J, McCachren SS et al. A Phase II trial of vinorelbine tartrate in patients with disseminated malignant melanoma and one prior systemic therapy: a Southwest Oncology Group study. Cancer100(8), 1699–1704 (2004).
   PubMed Web of Science ®Google Scholar
• Jimeno A, Hitt R, Quintela-Fandino M, Cortes-Funes H. Phase II trial of vinorelbine tartrate in patients with treatment-naive metastatic melanoma. Anticancer Drugs16(1), 53–57 (2005).
   PubMed Web of Science ®Google Scholar
• Clamon G, Sinkey C, Jochimsen P. Phase II study of dibromodulcitol and BCNU in metastatic malignant melanoma. Am. J. Clin. Oncol.8(3), 244–246 (1985).
   PubMed Web of Science ®Google Scholar
• Voigt H, Meigel WN, Meissner K et al. [Experiences with high-dose cisplatin therapy in metastasized malignant melanoma]. Onkologie5(3), 120–129 (1982).
   PubMed Web of Science ®Google Scholar
• Avril MF, Aamdal S, Grob JJ et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a Phase III study. J. Clin. Oncol.22(6), 1118–1125 (2004).
   PubMed Web of Science ®Google Scholar
• Luikart SD, Kennealey GT, Kirkwood JM. Randomized Phase III trial of vinblastine, bleomycin, and cis-dichlorodiammine-platinum versus dacarbazine in malignant melanoma. J. Clin. Oncol.2(3), 164–168 (1984).
   PubMed Web of Science ®Google Scholar
• Jungnelius U, Ringborg U, Aamdal S et al. Dacarbazine-vindesine versus dacarbazine–vindesine–cisplatin in disseminated malignant melanoma. A randomised Phase III trial. Eur. J. Cancer34(9), 1368–1374 (1998).
   PubMed Web of Science ®Google Scholar
• Bos JL. Ras oncogenes in human cancer: a review. Cancer Res.49(17), 4682–4689 (1989).
   PubMed Web of Science ®Google Scholar
• Ball NJ, Yohn JJ, Morelli JG et al. Ras mutations in human melanoma: a marker of malignant progression. J. Invest. Dermatol.102(3), 285–290 (1994).
   PubMed Web of Science ®Google Scholar
• Platz A, Ringborg U, Brahme EM, Lagerlof B. Melanoma metastases from patients with hereditary cutaneous malignant melanoma contain a high frequency of N-ras activating mutations. Melanoma Res.4(3), 169–177 (1994).
   PubMed Web of Science ®Google Scholar
• van ‘t Veer LJ, Burgering BM, Versteeg R et al. N-ras mutations in human cutaneous melanoma from sun-exposed body sites. Mol. Cell. Biol.9(7), 3114–3116 (1989).
   PubMed Web of Science ®Google Scholar
• Adjei AA. Blocking oncogenic Ras signaling for cancer therapy. J. Natl Cancer Inst.93(14), 1062–1074 (2001).
   PubMed Web of Science ®Google Scholar
• Gajewski TF, Niedzwiecki D, Johnson J et al. Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma: CALGB 500104. J. Clin. Oncol.24(18 Suppl.) (2006) (Abstract 8014).
   Google Scholar
• Beeram M, Patnaik A, Rowinsky EK. Raf: a strategic target for therapeutic development against cancer. J. Clin. Oncol.23(27), 6771–6790 (2005).
   PubMed Web of Science ®Google Scholar
• Wajapeyee N, Serra RW, Zhu X, Mahalingam M, Green MR. Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell132(3), 363–374 (2008).
   PubMed Web of Science ®Google Scholar
• Sharma A, Trivedi NR, Zimmerman MA et al. Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res.65(6), 2412–2421 (2005).
   PubMed Web of Science ®Google Scholar
• Eisen T, Ahmad T, Flaherty KT et al. Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br. J. Cancer95(5), 581–586 (2006).
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Schiller J, Schuchter LM et al. A Phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel. Clin. Cancer Res.14(15), 4836–4842 (2008).
   PubMed Web of Science ®Google Scholar
• Smalley KS, Xiao M, Villanueva J et al. CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations. Oncogene28(1), 85–94 (2009).
   PubMed Web of Science ®Google Scholar
• Agarwala SS, Keilholz U, Hogg D et al. Randomized Phase III study of paclitaxel plus carboplatin with or without sorafenib as second-line treatment in patients with advanced melanoma. J. Clin. Oncol.25(18 Suppl.) (2007) (Abstract 8510).
   PubMed Web of Science ®Google Scholar
• Fecher LA, Amaravadi R, Schuchter LM. Effectively targeting BRAF in melanoma: a formidable challenge. Pigment Cell Melanoma Res.21(4), 410–411 (2008).
   PubMed Web of Science ®Google Scholar
• Tsai J, Lee JT, Wang W et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc. Natl Acad. Sci. USA105(8), 3041–3046 (2008).
   PubMed Web of Science ®Google Scholar
• Solit DB, Garraway LA, Pratilas CA et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature439(7074), 358–362 (2006).
   PubMed Web of Science ®Google Scholar
• Haass NK, Sproesser K, Nguyen TK et al. The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. Clin. Cancer Res.14(1), 230–239 (2008).
   PubMed Web of Science ®Google Scholar
• Adjei AA, Cohen RB, Franklin W et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J. Clin. Oncol.26(13), 2139–2146 (2008).
   PubMed Web of Science ®Google Scholar
• Lorusso PM, Adjei AA, Varterasian M et al. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J. Clin. Oncol.23(23), 5281–5293 (2005).
   PubMed Web of Science ®Google Scholar
• Lorusso P, Krishnamurthi S, Rinehart JR et al. A Phase 1–2 clinical study of a second generation oral MEK inhibitor, PD 0325901 in patients with advanced cancer. J. Clin. Oncol.23(16 Suppl.) (2005) (Abstract 3011).
   Google Scholar
• Wymann MP, Marone R. Phosphoinositide 3-kinase in disease: timing, location, and scaffolding. Curr. Opin Cell. Biol.17(2), 141–149 (2005).
   PubMed Web of Science ®Google Scholar
• Guldberg P, thor Straten P, Birck A et al. Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res.57(17), 3660–3663 (1997).
   PubMed Web of Science ®Google Scholar
• Tsao H, Zhang X, Benoit E, Haluska FG. Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines. Oncogene16(26), 3397–3402 (1998).
   PubMed Web of Science ®Google Scholar
• Tsao H, Zhang X, Fowlkes K, Haluska FG. Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines. Cancer Res.60(7), 1800–1804 (2000).
   PubMed Web of Science ®Google Scholar
• Margolin K, Longmate J, Baratta T et al. CCI-779 in metastatic melanoma: a Phase II trial of the California Cancer Consortium. Cancer104(5), 1045–1048 (2005).
   PubMed Web of Science ®Google Scholar
• Thallinger C, Poeppl W, Pratscher B et al. CCI-779 plus cisplatin is highly effective against human melanoma in a SCID mouse xenotranplantation model. Pharmacology79(4), 207–213 (2007).
   PubMed Web of Science ®Google Scholar
• Thallinger C, Werzowa J, Poeppl W et al. Comparison of a treatment strategy combining CCI-779 plus DTIC versus DTIC monotreatment in human melanoma in SCID mice. J. Invest. Dermatol.127(10), 2411–2417 (2007).
   PubMed Web of Science ®Google Scholar
• Nakahara M, Isozaki K, Hirota S et al. A novel gain-of-function mutation of c-kit gene in gastrointestinal stromal tumors. Gastroenterology115(5), 1090–1095 (1998).
   PubMed Web of Science ®Google Scholar
• Heinrich MC, Corless CL, Duensing A et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science299(5607), 708–710 (2003).
   PubMed Web of Science ®Google Scholar
• Taniguchi M, Nishida T, Hirota S et al. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res.59(17), 4297–4300 (1999).
   PubMed Web of Science ®Google Scholar
• Faivre S, Delbaldo C, Vera K et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J. Clin. Oncol.24(1), 25–35 (2006).
   PubMed Web of Science ®Google Scholar
• Willmore-Payne C, Holden JA, Tripp S, Layfield LJ. Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis. Hum. Pathol.36(5), 486–493 (2005).
   PubMed Web of Science ®Google Scholar
• Shen SS, Zhang PS, Eton O, Prieto VG. Analysis of protein tyrosine kinase expression in melanocytic lesions by tissue array. J. Cutan. Pathol.30(9), 539–547 (2003).
   PubMed Web of Science ®Google Scholar
• Ugurel S, Hildenbrand R, Zimpfer A et al. Lack of clinical efficacy of imatinib in metastatic melanoma. Br. J. Cancer92(8), 1398–1405 (2005).
   PubMed Web of Science ®Google Scholar
• Wyman K, Atkins MB, Prieto V et al. Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer106(9), 2005–2011 (2006).
   PubMed Web of Science ®Google Scholar
• Beadling C, Jacobson-Dunlop E, Hodi FS et al.KIT gene mutations and copy number in melanoma subtypes. Clin. Cancer Res.14(21), 6821–6828 (2008).
   PubMed Web of Science ®Google Scholar
• Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J. Clin. Oncol.24(26), 4340–4346 (2006).
   PubMed Web of Science ®Google Scholar
• Ashida A, Takata M, Murata H, Kido K, Saida T. Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas. Int. J. Cancer124(4), 862–868 (2009).
   PubMed Web of Science ®Google Scholar
• Hodi FS, Friedlander P, Corless CL et al. Major response to imatinib mesylate in KIT-mutated melanoma. J. Clin. Oncol.26(12), 2046–2051 (2008).
   PubMed Web of Science ®Google Scholar
• Chaudhury TK, Lerner MP, Nordquist RE. Angiogenesis by human melanoma and breast cancer cells. Cancer Lett.11(1), 43–49 (1980).
   PubMed Web of Science ®Google Scholar
• Folkman J, Merler E, Abernathy C, Williams G. Isolation of a tumor factor responsible for angiogenesis. J. Exp. Med.133(2), 275–288 (1971).
   PubMed Web of Science ®Google Scholar
• Hubler WR Jr, Wolf JE Jr. Melanoma. Tumor angiogenesis and human neoplasia. Cancer38(1), 187–192 (1976).
   PubMed Web of Science ®Google Scholar
• Pawlak WZ, Legha SS. Phase II study of thalidomide in patients with metastatic melanoma. Melanoma Res.14(1), 57–62 (2004).
   PubMed Web of Science ®Google Scholar
• Reiriz AB, Richter MF, Fernandes S et al. Phase II study of thalidomide in patients with metastatic malignant melanoma. Melanoma Res.14(6), 527–531 (2004).
   PubMed Web of Science ®Google Scholar
• Danson S, Lorigan P, Arance A et al. Randomized Phase II study of temozolomide given every 8 hours or daily with either interferon a-2b or thalidomide in metastatic malignant melanoma. J. Clin. Oncol.21(13), 2551–2557 (2003).
   PubMed Web of Science ®Google Scholar
• Hwu WJ, Krown SE, Menell JH et al. Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. J. Clin. Oncol.21(17), 3351–3356 (2003).
   PubMed Web of Science ®Google Scholar
• Hwu WJ, Krown SE, Panageas KS et al. Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial. J. Clin. Oncol.20(11), 2610–2615 (2002).
   PubMed Web of Science ®Google Scholar
• Laber DA, Okeke RI, Arce-Lara C et al. A Phase II study of extended dose temozolomide and thalidomide in previously treated patients with metastatic melanoma. J. Cancer Res. Clin. Oncol.132(9), 611–616 (2006).
   PubMed Web of Science ®Google Scholar
• Atkins MB, Sosman JA, Agarwala S et al. Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a Phase II Cytokine Working Group study. Cancer113(8), 2139–2145 (2008).
   PubMed Web of Science ®Google Scholar
• Hwu WJ, Lis E, Menell JH et al. Temozolomide plus thalidomide in patients with brain metastases from melanoma: a Phase II study. Cancer103(12), 2590–2597 (2005).
   PubMed Web of Science ®Google Scholar
• Krown SE, Niedzwiecki D, Hwu WJ et al. Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102). Cancer107(8), 1883–1890 (2006).
   PubMed Web of Science ®Google Scholar
• Fruehauf JP, Lutzky J, McDermott DF et al.Axitinib (AG-013736) in patients with metastatic melanoma: a Phase II study. J. Clin. Oncol.26, 9006 (2008).
   Google Scholar
• Varker KA, Biber JE, Kefauver C et al. A randomized Phase 2 trial of bevacizumab with or without daily low-dose interferon α-2b in metastatic malignant melanoma. Ann. Surg. Oncol.14(8), 2367–2376 (2007).
   PubMed Web of Science ®Google Scholar
• Gonzalez-Cao M, Viteri S, Diaz-Lagares A et al. Preliminary results of the combination of bevacizumab and weekly paclitaxel in advanced melanoma. Oncology74(1–2), 12–16 (2008).
   PubMed Web of Science ®Google Scholar
• Perez DG, Suman VJ, Fitch TR et al. Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A. Cancer115(1), 119–127 (2009).
   PubMed Web of Science ®Google Scholar
• Grossman D, McNiff JM, Li F, Altieri DC. Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J. Invest. Dermatol.113(6), 1076–1081 (1999).
   PubMed Web of Science ®Google Scholar
• Panka DJ, Mano T, Suhara T, Walsh K, Mier JW. Phosphatidylinositol 3-kinase/Akt activity regulates c-FLIP expression in tumor cells. J. Biol. Chem.276(10), 6893–6896 (2001).
   PubMed Web of Science ®Google Scholar
• Selzer E, Schlagbauer-Wadl H, Okamoto I et al. Expression of Bcl-2 family members in human melanocytes, in melanoma metastases and in melanoma cell lines. Melanoma Res.8(3), 197–203 (1998).
   PubMed Web of Science ®Google Scholar
• Tang L, Tron VA, Reed JC et al. Expression of apoptosis regulators in cutaneous malignant melanoma. Clin. Cancer Res.4(8), 1865–1871 (1998).
   PubMed Web of Science ®Google Scholar
• Jansen B, Schlagbauer-Wadl H, Brown BD et al. bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat. Med.4(2), 232–234 (1998).
   PubMed Web of Science ®Google Scholar
• Jansen B, Wacheck V, Heere-Ress E et al. Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet356(9243), 1728–1733 (2000).
   PubMed Web of Science ®Google Scholar
• Bedikian AY, Millward M, Pehamberger H et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J. Clin. Oncol.24(29), 4738–4745 (2006).
   PubMed Web of Science ®Google Scholar
• Cragg MS, Jansen ES, Cook M et al. Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic. J. Clin. Invest.118(11), 3651–3659 (2008).
   PubMed Web of Science ®Google Scholar
• Miller LA, Goldstein NB, Johannes WU et al. BH3 mimetic ABT-737 and a proteasome inhibitor synergistically kill melanomas through noxa-dependent apoptosis. J. Invest. Dermatol.129, 964–971 (2009).
   PubMed Web of Science ®Google Scholar
• Sullivan RJ, Cohen MB, Atkins MB, Mier J, Cho D. In vitro synergy of the combination of sorafenib and abt-737 in melanoma cell lines. Presented at: 2009 AACR Annual Meeting. Denver, CO, USA, 18–22 April 2009 (Abstract 5501).
   Google Scholar
• Hassan M, Alaoui A, Feyen O et al. The BH3-only member Noxa causes apoptosis in melanoma cells by multiple pathways. Oncogene27(33), 4557–4568 (2008).
   PubMed Web of Science ®Google Scholar
• Qin JZ, Ziffra J, Stennett L et al. Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res.65(14), 6282–6293 (2005).
   PubMed Web of Science ®Google Scholar
• Amiri KI, Horton LW, LaFleur BJ, Sosman JA, Richmond A. Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma. Cancer Res.64(14), 4912–4918 (2004).
   PubMed Web of Science ®Google Scholar
• Markovic SN, Geyer SM, Dawkins F et al. A Phase II study of bortezomib in the treatment of metastatic malignant melanoma. Cancer103(12), 2584–2589 (2005).
   PubMed Web of Science ®Google Scholar
• Gradilone A, Gazzaniga P, Ribuffo D et al.Survivin, bcl-2, bax, and bcl-X gene expression in sentinel lymph nodes from melanoma patients. J. Clin. Oncol.21(2), 306–312 (2003).
   PubMed Web of Science ®Google Scholar
• Piras F, Murtas D, Minerba L et al. Nuclear survivin is associated with disease recurrence and poor survival in patients with cutaneous malignant melanoma. Histopathology50(7), 835–842 (2007).
   PubMed Web of Science ®Google Scholar
• Takeuchi H, Morton DL, Elashoff D, Hoon DS. Survivin expression by metastatic melanoma predicts poor disease outcome in patients receiving adjuvant polyvalent vaccine. Int. J. Cancer117(6), 1032–1038 (2005).
   PubMed Web of Science ®Google Scholar
• Grossman D, Kim PJ, Schechner JS, Altieri DC. Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc. Natl Acad. Sci. USA98(2), 635–640 (2001).
   PubMed Web of Science ®Google Scholar
• Gonzalez R, Lewis K, Samlowski W et al. A Phase II study of YM155, a novel survivin suppressant, administered by 168 hour continuous infusion in patients with unresectable stage III or stage IV melanoma. J. Clin. Oncol.25(18 Suppl.) (2007) (Abstract 8538).
   Google Scholar
• Kirshner JR, He S, Balasubramanyam V et al. Elesclomol induces cancer cell apoptosis through oxidative stress. Mol. Cancer. Ther.7(8), 2319–2327 (2008).
   PubMed Web of Science ®Google Scholar
• Gonzalez R, Lawson DH, Weber RW et al. Phase II trial of elesclomol (formerly STA-4783) and paclitaxel in stage IV metastatic melanoma (MM): subgroup analysis by prior chemotherapy. J. Clin. Oncol.26(Suppl.) (2008) (Abstract 9036).
   Google Scholar
• Zhang L, Huang J, Yang N et al. microRNAs exhibit high frequency genomic alterations in human cancer. Proc. Natl Acad. Sci. USA103(24), 9136–9141 (2006).
   PubMed Web of Science ®Google Scholar
• Gaur A, Jewell DA, Liang Y et al. Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res.67(6), 2456–2468 (2007).
   PubMed Web of Science ®Google Scholar
• Molnar V, Tamasi V, Bakos B, Wiener Z, Falus A. Changes in miRNA expression in solid tumors: an miRNA profiling in melanomas. Sem. Cancer Biol.18(2), 111–122 (2008).
   PubMed Web of Science ®Google Scholar